Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Restructures, Lays Off 30 Percent of Staff; New Products, Including Cheaper MassArray, to Drive Growth


Sequenom, beset by meager share prices and a rapidly evolving marketplace, will lay off around 30 percent of its workforce, or 44 staffers, in a large-scale restructuring aimed at cutting costs and redirecting resources.

The step is expected to save the San Diego company between $7 million and $9 million in cash burn next year after recording a $1 million charge in severance and other costs.

Sequenom, which will receive a Nasdaq delisting warning letter tomorrow if its stock closes below $1, also said it will "consider additional steps to raise capital including accessing financial markets and advancing strategic partnerships."

"Currently, we are in the process of stabilizing the core genetic analysis business and focusing on initiatives with high growth prospects," Harry Stylli, Sequenom's new president and CEO, said in a statement today. "In parallel, Sequenom has prioritized key product and service initiatives that, in due course, are expected to drive growth and create value.

"Further, Sequenom's core technology is demonstrating emerging utility in the molecular diagnostics market," he continued. "We expect to capitalize on our promising potential in this large and fast growing market primarily through key strategic partnerships."

As part of the restructuring, Sequenom intends to focus on its flagship MassArray platform and its iPlex multiplexing assay. It also said it plans to launch several new applications for use with its MassArray system within the next year.

Specifically, the company said it plans to offer products and services for quantitative gene expression and methylation services; launch a series of applications that will "significantly" reduce cost per genotype beginning with the iPlex multiplexing assay; develop multiplexed quantitative methylation and multiplexed QGE for "fine mapping and molecular diagnostics; launch a "cost effective" MassArray product for lower-throughput users; and take advantage of internally developed biomarkers in hopes of sparking developmental partnerships.

Among other steps, Sequenom said it plans to "evaluate opportunities to license IP to more broadly enable the analysis of nucleic acids by mass spectrometry." The company's MassArray platform is based on mass spec.

In addition, Sequenom said chief financial officer Steve Zaniboni will step down during the fourth quarter because the company plans to consolidate the CFO position with that of the vice president of finance. That position is currently held by John Sharp.

Lastly, Sequenom said it has negotiated a rent deferral of approximately $3.2 million over two years for its corporate headquarters, and continues to explore subleasing options for this facility. The company is also taking steps to lower costs by reviewing its key supplier relationships.

Filed under

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.